NCT06592027View on ClinicalTrials.gov

Dexmedetomidine for Attenuation of Pressor Response

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

May 1, 2024

Study Completion Date

May 30, 2024

Conditions
Pressor Response
Interventions
DRUG

PRECEDEX INJ★ 2ML

this group will receive single dose of dexmedetomidine 0.5 mcg /kg in 50 ml normal saline over 10 min IV infusion

DRUG

PRECEDEX INJ★ 2ML

single dose of dexmedetomidine 1 mcg /kg in 50 ml normal saline over 10 min IV infusion

Trial Locations (1)

02

Theodor Bilharz Research institute, Giza

All Listed Sponsors
lead

Theodor Bilharz Research Institute

OTHER

NCT06592027 - Dexmedetomidine for Attenuation of Pressor Response | Biotech Hunter | Biotech Hunter